Teva receives Notice of Compliance from Health Canada to market generic version of Lipitor Tablets

Published on May 20, 2010 at 2:04 AM · No Comments

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its subsidiary, Teva Canada received a Notice of Compliance from Health Canada to market its generic version of Pfizer's Lipitor® (atorvastatin) Tablets, a product indicated for lowering cholesterol. Shipment of this product will commence immediately.

Lipitor (atorvastatin) Tablets had annual brand sales of approximately C$1.3 billion in Canada.

SOURCE Teva Pharmaceutical Industries Ltd.

91585d63-d665-4aa0-b5ba-c3fcc4c43285|0|.0

Posted in: Pharmaceutical News

Tags: Atorvastatin, Biotechnology, Cholesterol, Lipitor (Atorvastatin), Medicaid, Medicare, Pfizer, Protonix

Prior News EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent
Next News St. Jude Medical to acquire LightLab for $90M in cash

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Post a new comment

(Logout)

Quirky Comment Title (optional)

Post

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.